Abstract

In 2016, a new technique to edit genes was made public: the CRISPR-CAS9. Five years later, we can examine the advancement of this biotechnology from bioethics. It is evident that the gene-editing technique on the somatic line has been disseminated and is starting to show some results. Nonetheless, it is impossible to extend this work to the germlines through heritable human genome editing. Two documents are studied, the International Commission for the Clinical Use of Human Germline Genome Editing report and the World Health Organization Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing report, reflecting on their content and consequences.